Renaissance Small Cap Growth Strategy Adds ADMA Biologics to Portfolio in Q2

Renaissance Investment Management added ADMA Biologics (ADMA) to its portfolio in Q2. ADMA Biologics is a biopharmaceutical company providing plasma-based biologics for immune deficiencies and infectious disease prevention. The company has a strategy to be an end-to-end provider of plasma-derived biologics addressing unmet needs. ADMA's largest product, Asceniv, has penetrated 3-5% of the target population, and demand is outstripping supply. The company aims to reach $1.0 billion in revenue by 2030.

In a recent development, Renaissance Investment Management has incorporated ADMA Biologics (ADMA) into its portfolio during the second quarter. ADMA Biologics is a biopharmaceutical company specializing in plasma-based biologics for immune deficiencies and infectious disease prevention. The company aims to be an end-to-end provider of plasma-derived biologics, addressing unmet medical needs.

ADMA's largest product, Asceniv, has achieved penetration of 3-5% in its target population, with demand significantly outstripping supply. The company has set an ambitious goal to reach $1.0 billion in revenue by 2030. This strategic addition by Renaissance Investment Management underscores confidence in ADMA's growth potential and market position.

ADMA Biologics' stock ended the recent trading session at $15.30, marking a decline of 5.03% compared to the previous day's closing price. This performance lagged the S&P 500's daily gain of 0.47%. Over the past month, ADMA's stock has fallen by 5.18%, underperforming the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

Analysts expect ADMA Biologics to post earnings of $0.16 per share in its upcoming report, representing year-over-year growth of 6.67%. Revenue is projected to reach $130.1 million, up 8.56% from the prior-year quarter. For the entire fiscal year, Zacks Consensus Estimates project earnings of $0.57 per share and revenue of $506.7 million, indicating changes of +16.33% and +18.82%, respectively, from the prior year Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

The Zacks Rank for ADMA Biologics is currently #3 (Hold), suggesting a neutral outlook. The company's Forward P/E ratio stands at 28.26, which is higher than the industry average of 19.79. The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 95, placing it in the top 39% of all industries Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note^[1].

Renaissance Investment Management's addition of ADMA Biologics to its portfolio signals a strategic move, aligning with the company's long-term growth prospects. As ADMA continues to expand its product portfolio and market reach, investors will closely monitor its financial results and analyst revisions for insights into future performance.